

Thoracic Disease-Oriented Team

Clinical Research Treatment Flowchart



ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

ALK

1L

2L

UCI 21-241 (Nuvalent)
 NVL-655 + ALK inhibitor

Mechanism: TKI Inhibitor
 Coord: Keagan Buttigieg
 Accrual: 13/30

ALK Mutations



ADVANCED/METASTATIC

Exon 18

Open to Accrual

Low Accruing

Pending Activation

Exon 19 del or L858R

1L

2L

UCI 23-95 (HARMONI)

Randomized Double Blind:
AK112/Placebo + Pem + Carbo

Mechanism: Novel PD-1/VEGF
bispecific antibody w/ Chemo
Coord: Celest Ramirez
Accrual: 2/8

UCI 22-121 (Jintsbio)
JIN-A02 Monotherapy

Mechanism: TKI
Coord: Richard Chang
Accrual: 0/12

UCI 22-217(Janssen)
Amivantamb + Lazertinib w/ or
without Carbo + Pemetrexed

Mechanism: Antibody drug w/
TKI and Chemo
Coord: Celest Ramirez
Accrual: 4/10



Exon 20

Exon 21

1L

UCI 22-217(Janssen)
 Amivantamb + Lazertinib w/ or without Carbo + Pemetrexed

Mechanism: Antibody drug w/ TKI and Chemo
 Coord: Celest Ramirez
 Accrual: 4/10


2L

UCI 23-95 (HARMONI)
 Randomized Double Blind: AK112/Placebo + Pem + Carbo

Mechanism: Novel PD-1/VEGF bispecific antibody w/ Chemo
 Coord: Celest Ramirez
 Accrual: 2/8



Stage 1A / Adjuvant

 Open to Accrual

 Low Accruing

 Pending Activation

UCI 22-59 (ADAURA)

Randomized: Osimertinib or Placebo

Mechanism: TKI
Coord: Jenny Choe
Accrual: 1/20



ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

cMET and EGFR

1L

2L

UCI 20-195 (MCLA-129)

Mechanism: Antibody Drug
Coord: Keagan Buttigieg
Accrual: 12/25

cMET Mutations



ADVANCED/METASTATIC

1L

UCI 23-66 (Boehringer Ingelheim)

BI-1810631 Monotherapy

Mechanism: TKI
Cord: Keagan Buttigieg
Accrual: 0/8

2L

Exon 19

Exon 20

UCI 21-234 (AstraZeneca)

Randomized: Arm 1: T-DXD(Trastuzumab Deruxtecan) or Arm 2: Cisplatin or Carbo + Pemetrexed + Pembrolizumab

*Treatment Naïve for palliative intent systemic therapy in locally advanced or metastatic disease.

*Documented Her2 Exon 19 or 20 mutation

*Tumor sample must be available for central testing from fresh or archival.

*No Slot Required prior to consenting if mutation of HER2 is available.

Accrual: 1/20

ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

KRAS G12C

G12A, G12D, G12R, G12S,
G12V

1L

UCI 22-30 (D3S-001-100):
D3 Bio

Mechanism: TKI
Coord: Richard Chang
Accrual: 0/5

2L

UCI 22-88 (RMC-6291
Revolution Med)

Mechanism: TKI
Coord: Richard Chang
Accrual: 4/30

UCI 23-116 (RMC-6291
Revolution Medicine)

Mechanism: TKI
Coordinator: TBD
Accrual: 0/15

UCI 21-53 (Loxo Oncology,
Inc. LOXO-RAS-20001

Mechanism: TKI
Coord: Jenny Choe
Accrual: 6/16


UCI 18-78 (Mirati MRTX-
849)

Mechanism: TKI
Coord: Celest Ramirez
24/50

UCI 22-87 (RMC-6236
Revolution Med)

Mechanism: TKI
Coordinator: Oliver Quines
Accrual: 14/30



 Open to Accrual

 Low Accruing

 Pending Activation

ADVANCED/METASTATIC

NRG-LU007

Treatment: (Randomized) Group 1:
Atezolizumab Alone. Group 2:
Atezolizumab + Radiation

Mechanism: Immunotherapy + Radiation
Coord: Richard Chang
Accrual: 1/10

UCI 23-178

Treatment: BL-B01D1 IV
Mechanism: IP binding to EGFR/HER3,
antibody fragments of IP bind to
EGFR/HER3, Fc segment of (ADCC)
Coord: TBA
Accrual: 0/17



ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

NTRK 1-3

1L

2L

UCI 16-79 (TPX-0005)

Mechanism: TKI
 Coord: Stephanie Fernandez
 Accrual: 17/35

NTRK Mutations

ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

All Comers

3L

ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

ROR2

1L

2L



ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

ROS1

1L

2L


UCI 21-47 (NVL-520 Nuvalent)

Mechanism: TKI
 Coord: Keagan Buttigieg
 Accrual: 9/28

ROS1 Mutations



Database & Repository

 Open to Accrual

 Low Accruing

 Pending Activation

UCI 21-238: Database & Repository of Asian female never smokers w/ low dose CT scan Screening Study

Mechanism: D
Coord: TBD
Accrual: 0/100



■ Open to Accrual

■ Low Accruing

■ Pending Activation

Advanced / Metastatic

1L

UCI 21-242: Ph III Durvalumab Combo w/Dato-DXd vs Pembro


Mechanism: Chemo + experimental drug
Coord: Celest Ramirez
Accrual: 0/12

2L

UCI 23-148: CJRB-01 (oral) + Pembrolizumab

Mechanism: Live biotherapeutic product containing a novel strain belonging in the species *Leuconostoc mesenteroides* (*L. mesenteroides* + Pembrolizumab)
Coord: TBD
Accrual: 0/12




 Open to Accrual

 Low Accruing

 Pending Activation

UCI 22-86: Gut Microbiome Study

Mechanism: Fecal Collection
Coord: Stefanie Fernandez
Accrual: 1/100

 Open to Accrual

 Low Accruing

 Pending Activation